Novo Nordisk has opened a new manufacturing facility in the Kaluga region of Russia for the production of modern devices for administering insulin for treating diabetes. The facility will produce both Penfill® cartridges and FlexPen® prefilled insulin injection pens for the Russian market, according to FiercePharma.
The new facility is located in Technopark Grabtsevo and created about 150 new jobs. “The manufacturing facility in Kaluga is a sign of our long-term commitment to people with diabetes in Russia, where close to 10 million people have the disease according to local studies. With our investment in local manufacturing, we ensure availability of high-quality modern insulins to the people with diabetes in Russia who rely on our products every day,” said Lars Rebien Sørensen, CEO of Novo Nordisk.
The facility will be operating in accordance with current Good Manufacturing Practices (GMP). This is the first and only greenfield facility for the manufacturing of modern insulin in Russia. Environmental targets for carbon dioxide emission, water consumption and energy useage have been established.
“The opening of the Novo Nordisk manufacturing facility in Kaluga is a sign of confidence in our region, as well as an important stage in the formation of a pharmaceutical cluster in Kaluga. I am convinced that the new facility will have a significant impact on improving the quality of life for people with diabetes in Kaluga as well as in the rest of Russia,” said Kaluga Region Governor Anatoly Artamonov.
Novo Nordisk also has production sites in Denmark, Brazil, China, France and the U.S.